Rush University Medical Center is a nationally ranked academic medical center in the Illinois Medical District neighborhood of Chicago, Illinois.

There are 664 beds in Rush Presbyterian St. Lukes.

During the past decade, Rush Presbyterian St. Lukes conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rush Presbyterian St. Lukes" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 3 trials, followed by "AIDS Clinical Trials Group" with 1 trials sponsored, "Abbott" with 1 trials sponsored, "Baxalta now part of Shire" with 1 trials sponsored and "New York Presbyterian Hospital" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rush Presbyterian St. Lukes" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Manchester University NHS Foundation Trust" with 1 trials as a collaborator and "National Institute of Allergy and Infectious Diseases (NIAID)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Rush Presbyterian St. Lukes" are "HIV Infections" (4 trials), "Bipolar Disorder" (1 trials), "Hemophilia A" (1 trials) and "Hemophilia A With Inhibitors" (1 trials). Many other conditions were trialed in "Rush Presbyterian St. Lukes" in a lesser frequency.

Most popular intervention types in "Rush Presbyterian St. Lukes" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atazanavir" (1 trials), "Didanosine (enteric-coated)" (1 trials), "Divalproex Sodium (Delayed-Release Tablets)" (1 trials), "Divalproex Sodium (Extended-Release Tablets)" (1 trials) and "Efavirenz" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rush Presbyterian St. Lukes" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Rush Presbyterian St. Lukes". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Rush Presbyterian St. Lukes, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Rush Presbyterian St. Lukes, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".